EWTX Projected Dividend Yield
Edgewise Therapeutics Inc ( NASDAQ : EWTX )Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe, rare muscle disorders. Co.'s primary product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Using its proprietary drug discovery platform, Co. is developing a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a range of genetically defined muscle disorders. 20 YEAR PERFORMANCE RESULTS |
EWTX Dividend History Detail EWTX Dividend News EWTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |